Pre-made Tavolixizumab benchmark antibody ( Whole mAb, anti-TNFSF4/OX40 therapeutic antibody, Anti-CD134L/CD252/GP34/OX-40L/OX4OL/TNLG2B/TXGP1 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Tavolixizumab biosimilar, Whole mAb, Anti-TNFSF4/OX40 Antibody: Anti-CD134L/CD252/GP34/OX-40L/OX4OL/TNLG2B/TXGP1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Products Name (INN Index) | Pre-Made Tavolixizumab biosimilar, Whole mAb, Anti-TNFSF4/OX40 Antibody: Anti-CD134L/CD252/GP34/OX-40L/OX4OL/TNLG2B/TXGP1 therapeutic antibody |
|---|---|
| INN Name | Tavolixizumab |
| Target | TNFSF4 |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2016 |
| Year Recommended | 2018 |
| Companies | European Network of Gynaecological Oncological Trial Groups,MedImmune |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Ovarian cancer,Solid tumours |
| Development Tech | NA |
| Previous Name | tavolimab |
| Gm Offical Target Name | TNFSF4 |
| Package |
